JP2019533690A - 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子 - Google Patents

癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子 Download PDF

Info

Publication number
JP2019533690A
JP2019533690A JP2019522771A JP2019522771A JP2019533690A JP 2019533690 A JP2019533690 A JP 2019533690A JP 2019522771 A JP2019522771 A JP 2019522771A JP 2019522771 A JP2019522771 A JP 2019522771A JP 2019533690 A JP2019533690 A JP 2019533690A
Authority
JP
Japan
Prior art keywords
cancer
tumor
arenavirus
protein
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019522771A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533690A5 (https=
Inventor
シュミット サラ
シュミット サラ
オルリンジャー クラウス
オルリンジャー クラウス
ステファニー リング サンドラ
ステファニー リング サンドラ
ローランド フラッツ ルーカス
ローランド フラッツ ルーカス
Original Assignee
ホオキパ バイオテック ジーエムビーエイチ
ホオキパ バイオテック ジーエムビーエイチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ホオキパ バイオテック ジーエムビーエイチ, ホオキパ バイオテック ジーエムビーエイチ filed Critical ホオキパ バイオテック ジーエムビーエイチ
Publication of JP2019533690A publication Critical patent/JP2019533690A/ja
Publication of JP2019533690A5 publication Critical patent/JP2019533690A5/ja
Priority to JP2022188395A priority Critical patent/JP2023029898A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019522771A 2016-11-04 2017-11-03 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子 Withdrawn JP2019533690A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022188395A JP2023029898A (ja) 2016-11-04 2022-11-25 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662417865P 2016-11-04 2016-11-04
US201662417891P 2016-11-04 2016-11-04
US62/417,865 2016-11-04
US62/417,891 2016-11-04
PCT/EP2017/078149 WO2018083220A2 (en) 2016-11-04 2017-11-03 Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022188395A Division JP2023029898A (ja) 2016-11-04 2022-11-25 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子

Publications (2)

Publication Number Publication Date
JP2019533690A true JP2019533690A (ja) 2019-11-21
JP2019533690A5 JP2019533690A5 (https=) 2020-12-17

Family

ID=60452580

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019522771A Withdrawn JP2019533690A (ja) 2016-11-04 2017-11-03 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子
JP2022188395A Pending JP2023029898A (ja) 2016-11-04 2022-11-25 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022188395A Pending JP2023029898A (ja) 2016-11-04 2022-11-25 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子

Country Status (7)

Country Link
US (2) US20200206334A1 (https=)
EP (1) EP3534943A2 (https=)
JP (2) JP2019533690A (https=)
CN (1) CN110167586B (https=)
AU (1) AU2017353443B2 (https=)
CA (1) CA3039356A1 (https=)
WO (1) WO2018083220A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2604695B1 (en) 2007-12-27 2022-11-16 Universität Zürich Replication-defective arenavirus vectors
CN115058452A (zh) 2013-12-03 2022-09-16 霍欧奇帕生物科技有限公司 Cmv疫苗
LT3218504T (lt) 2014-11-13 2020-09-10 Université De Geneve Trijų segmentų arenavirusai kaip vakcinos vektoriai
EP3307308A2 (en) 2015-06-10 2018-04-18 Hookipa Biotech AG Hpv vaccines
IL314371A (en) 2015-11-04 2024-09-01 Hookipa Biotech Gmbh Vaccines against hepatitis B virus
RS63546B1 (sr) 2015-11-12 2022-09-30 Hookipa Biotech Gmbh Čestice arenavirusa kao vakcine protiv kancera
JP2020514321A (ja) 2017-02-01 2020-05-21 モデルナティーエックス， インコーポレイテッド 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物
AU2018247958A1 (en) * 2017-04-07 2019-10-10 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors
DE102018215551A1 (de) * 2018-09-12 2020-03-12 Virolutions Biotech Gmbh Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten
CN117280027A (zh) 2021-03-23 2023-12-22 霍欧奇帕生物科技有限公司 用于治疗前列腺癌的沙粒病毒
CA3236106A1 (en) * 2021-11-08 2023-05-11 Henning Lauterbach Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016075250A1 (en) * 2014-11-13 2016-05-19 Université De Genève Tri-segmented arenaviruses as vaccine vectors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2604695B1 (en) 2007-12-27 2022-11-16 Universität Zürich Replication-defective arenavirus vectors
EP2968506B1 (en) 2013-03-15 2019-07-31 Université de Genève Anti-mycobacterial vaccines
CN115058452A (zh) 2013-12-03 2022-09-16 霍欧奇帕生物科技有限公司 Cmv疫苗
EP3307308A2 (en) * 2015-06-10 2018-04-18 Hookipa Biotech AG Hpv vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016075250A1 (en) * 2014-11-13 2016-05-19 Université De Genève Tri-segmented arenaviruses as vaccine vectors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CANCER IMMUNOL IMMUNOTHER., vol. 47, JPN6023014712, 1998, pages 1 - 12, ISSN: 0005033531 *
CANCER RES., 2014, VOL.74 NO.8, P.2171-2181, JPN6021046865, ISSN: 0004649871 *
NAT MED., 2010, VOL.16 NO.3, P.339-345, JPN6021046867, ISSN: 0004649872 *
PEDATR BLOOD CANCER., 2015, VOL.62 NO.5, P.743-750, JPN6022030507, ISSN: 0005033530 *
PLOS PATHOGENS, 2014, VOL.10 NO.2, P.E1003922, JPN6021046868, ISSN: 0004649873 *

Also Published As

Publication number Publication date
CA3039356A1 (en) 2018-05-11
CN110167586A (zh) 2019-08-23
JP2023029898A (ja) 2023-03-07
US20200206334A1 (en) 2020-07-02
AU2017353443A1 (en) 2019-05-02
WO2018083220A2 (en) 2018-05-11
AU2017353443B2 (en) 2024-11-14
EP3534943A2 (en) 2019-09-11
US20250009860A1 (en) 2025-01-09
WO2018083220A3 (en) 2018-12-13
CN110167586B (zh) 2024-01-30

Similar Documents

Publication Publication Date Title
JP7157662B2 (ja) 癌ワクチンとしてのアレナウイルス粒子
US20250009860A1 (en) Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
JP2020516601A (ja) 固形腫瘍を治療するためのアレナウイルス粒子
JP7781511B2 (ja) Ｔｅｒｔ免疫原性組成物及びそれを用いた治療方法
JP2019516410A (ja) ワクチンベクターとしての三セグメントピチンデウイルス
US20250073324A1 (en) Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies
CN114981443A (zh) 作为载体的沙粒病毒
US20250057931A1 (en) Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
HK40070799A (en) Arenavirus particles as cancer vaccines
HK1260579B (en) Arenavirus particles as cancer vaccines
HK1260579A1 (en) Arenavirus particles as cancer vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221125

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221125

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221213

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230210

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230213

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230414

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230418

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240905